search
Back to results

A Phase I/II Trial of Vaccine Therapy of HIV-1 Infected Individuals With 50-500 CD4 Cells/mm3

Primary Purpose

HIV Infections

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
rgp120/HIV-1MN
Zidovudine
Sponsored by
National Institute of Allergy and Infectious Diseases (NIAID)
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional prevention trial for HIV Infections focused on measuring Vaccines, Synthetic, HIV-1, Acquired Immunodeficiency Syndrome, AIDS-Related Complex, Zidovudine, HIV Envelope Protein gp120, AIDS Vaccines, HIV Therapeutic Vaccine

Eligibility Criteria

13 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria Required immediately prior to study entry: A minimum of 2 and a maximum of 12 months of AZT therapy at 500-600 mg/day (does not apply to the pilot group patients receiving vaccine only and to patients with CD4 counts of 50-199 cells/mm3). Concurrent Medication: Allowed: PCP prophylaxis. Rifabutin and clarithromycin (in patients with CD4 counts of 50-199 cells/mm3 only). Short-term nonsteroidal anti-inflammatory therapy for acute conditions. Short intermittent cycles of acyclovir. Patients must have: HIV infection, with CD4 count of 50-500 cells/mm3. No active opportunistic infection (patients with CD4 counts of 50-199 cells/mm3 may have a history of an opportunistic infection). Consent of parent, guardian, or person with power of attorney, if less than 18 years of age. B-cell lines established in order to be vaccinated. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Known or suspected allergies to any vaccine components. Concurrent Medication: Excluded: Agents with immunosuppressive activity. Antiretroviral therapies other than AZT (except in patients with CD4 counts of 50-199 cells/mm3). Interferon. Parenteral therapies (including SC allergy medications and chemotherapy for Kaposi's sarcoma). Steroids. Hematopoietins. Prior Medication: Excluded within 12 weeks prior to study entry: Agents with immunosuppressive activity. Antiretroviral therapies other than AZT (except in patients with CD4 counts of 50-349 cells/mm3). Interferon. Parenteral therapies (including SC allergy medications and chemotherapy for Kaposi's sarcoma). Steroids. Hematopoietins. Active drug abuse.

Sites / Locations

  • UCLA CARE Center CRS
  • Stanford CRS
  • Ucsf Aids Crs
  • University of Colorado Hospital CRS
  • Massachusetts General Hospital ACTG CRS
  • Bmc Actg Crs
  • Beth Israel Deaconess - East Campus A0102 CRS
  • Beth Israel Deaconess Med. Ctr., ACTG CRS
  • NY Univ. HIV/AIDS CRS
  • University of Washington AIDS CRS

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

First Posted
November 2, 1999
Last Updated
October 27, 2021
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators
Genentech, Inc., Glaxo Wellcome
search

1. Study Identification

Unique Protocol Identification Number
NCT00000755
Brief Title
A Phase I/II Trial of Vaccine Therapy of HIV-1 Infected Individuals With 50-500 CD4 Cells/mm3
Official Title
A Phase I/II Trial of Vaccine Therapy of HIV-1 Infected Individuals With 50-500 CD4 Cells/mm3
Study Type
Interventional

2. Study Status

Record Verification Date
October 2021
Overall Recruitment Status
Completed
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
March 1993 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators
Genentech, Inc., Glaxo Wellcome

4. Oversight

5. Study Description

Brief Summary
To examine the response of HIV-1 infected patients to vaccination with gp120/HIV-1MN antigen. To determine the effect of antiretroviral therapy on vaccine responsiveness. Fifty percent of HIV-1 infected individuals remain symptom free for 8-12 years. It has been hypothesized that HIV-specific immune responses are responsible for the period of relative quiescence of viral replication. Recent studies suggest that these immune functions can be augmented by vaccination with HIV-derived antigens.
Detailed Description
Fifty percent of HIV-1 infected individuals remain symptom free for 8-12 years. It has been hypothesized that HIV-specific immune responses are responsible for the period of relative quiescence of viral replication. Recent studies suggest that these immune functions can be augmented by vaccination with HIV-derived antigens. Patients are randomized to receive rgp120/HIV-1MN vaccine or alum adjuvant placebo by intramuscular injection at weeks 0, 4, 8, 12, 16, and 20, with or without daily oral zidovudine (AZT) or their current stable dose of antiretroviral therapy. After completing the primary vaccination series, patients are permitted to continue into an extension phase, in which they receive a booster vaccination at weeks 28, 36, and 44. Patients will be stratified by CD4 count: 350-500, 200-349, and 50-199 cells/mm3. A fourth group with counts of 350-500 cells/mm3 will serve as a pilot group and receive vaccine only.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV Infections
Keywords
Vaccines, Synthetic, HIV-1, Acquired Immunodeficiency Syndrome, AIDS-Related Complex, Zidovudine, HIV Envelope Protein gp120, AIDS Vaccines, HIV Therapeutic Vaccine

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Enrollment
168 (false)

8. Arms, Groups, and Interventions

Intervention Type
Biological
Intervention Name(s)
rgp120/HIV-1MN
Intervention Type
Drug
Intervention Name(s)
Zidovudine

10. Eligibility

Sex
All
Minimum Age & Unit of Time
13 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria Required immediately prior to study entry: A minimum of 2 and a maximum of 12 months of AZT therapy at 500-600 mg/day (does not apply to the pilot group patients receiving vaccine only and to patients with CD4 counts of 50-199 cells/mm3). Concurrent Medication: Allowed: PCP prophylaxis. Rifabutin and clarithromycin (in patients with CD4 counts of 50-199 cells/mm3 only). Short-term nonsteroidal anti-inflammatory therapy for acute conditions. Short intermittent cycles of acyclovir. Patients must have: HIV infection, with CD4 count of 50-500 cells/mm3. No active opportunistic infection (patients with CD4 counts of 50-199 cells/mm3 may have a history of an opportunistic infection). Consent of parent, guardian, or person with power of attorney, if less than 18 years of age. B-cell lines established in order to be vaccinated. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Known or suspected allergies to any vaccine components. Concurrent Medication: Excluded: Agents with immunosuppressive activity. Antiretroviral therapies other than AZT (except in patients with CD4 counts of 50-199 cells/mm3). Interferon. Parenteral therapies (including SC allergy medications and chemotherapy for Kaposi's sarcoma). Steroids. Hematopoietins. Prior Medication: Excluded within 12 weeks prior to study entry: Agents with immunosuppressive activity. Antiretroviral therapies other than AZT (except in patients with CD4 counts of 50-349 cells/mm3). Interferon. Parenteral therapies (including SC allergy medications and chemotherapy for Kaposi's sarcoma). Steroids. Hematopoietins. Active drug abuse.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Schooley RT
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Walker B
Official's Role
Study Chair
Facility Information:
Facility Name
UCLA CARE Center CRS
City
Los Angeles
State/Province
California
ZIP/Postal Code
90095
Country
United States
Facility Name
Stanford CRS
City
Palo Alto
State/Province
California
ZIP/Postal Code
943055107
Country
United States
Facility Name
Ucsf Aids Crs
City
San Francisco
State/Province
California
ZIP/Postal Code
941102859
Country
United States
Facility Name
University of Colorado Hospital CRS
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80262
Country
United States
Facility Name
Massachusetts General Hospital ACTG CRS
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Facility Name
Bmc Actg Crs
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02118
Country
United States
Facility Name
Beth Israel Deaconess - East Campus A0102 CRS
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
Facility Name
Beth Israel Deaconess Med. Ctr., ACTG CRS
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
Facility Name
NY Univ. HIV/AIDS CRS
City
New York
State/Province
New York
ZIP/Postal Code
10016
Country
United States
Facility Name
University of Washington AIDS CRS
City
Seattle
State/Province
Washington
ZIP/Postal Code
981224304
Country
United States

12. IPD Sharing Statement

Citations:
Citation
Kuritzkes DR, Spino C, Valentine F, Schooley RT. Association of plasma HIV-1 RNA, CD4 count, and immune response in patients with 50-500 CD4 cells/ul. Conf Retroviruses Opportunistic Infect. 1997 Jan 22-26;4th:204 (abstract no 757)
Results Reference
background
Citation
Schooley RT, Spino C, Chiu S, DeGruttola V, Kuritzkes DR. Poor immunogenicity of HIV-1 envelope vaccines with alum or MF59 aduvant in HIV-infected individuals: results of two randomized trials. Conf Retroviruses Opportunistic Infect. 1997 Jan 22-26;4th:204 (abstract no 756)
Results Reference
background
PubMed Identifier
11023459
Citation
Schooley RT, Spino C, Kuritzkes D, Walker BD, Valentine FA, Hirsch MS, Cooney E, Friedland G, Kundu S, Merigan TC Jr, McElrath MJ, Collier A, Plaeger S, Mitsuyasu R, Kahn J, Haslett P, Uherova P, deGruttola V, Chiu S, Zhang B, Jones G, Bell D, Ketter N, Twadell T, Chernoff D, Rosandich M. Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS Clinical Trials Groups 209 and 214. J Infect Dis. 2000 Nov;182(5):1357-64. doi: 10.1086/315860. Epub 2000 Oct 9.
Results Reference
background

Learn more about this trial

A Phase I/II Trial of Vaccine Therapy of HIV-1 Infected Individuals With 50-500 CD4 Cells/mm3

We'll reach out to this number within 24 hrs